Summit Therapeutics Share Discussion Threads

[waterloo01] 02/3/2017 14:33

Definitely buys and given the size must be a fund. Nice to back over £2.00 with headroom North. Question is, are they finished buying?

[hugus maximus] 02/3/2017 11:33

Gosh. Just looked in and see things are going up great guns! I never tire of attempting to work out how any of this works in terms of MM's reported trades .. something good is clearly going on ... is this what is known as "someone loading up in the background"?

EDIT 12.30 02/03/17 ... so ... there are half a million shares just reported as "Buys"

[chrisatrdg] 01/3/2017 21:15

Final NASDAQ close is $12.73 up 4.25% on a vol. of 16,525 which equates at $1.23 to £2.07 which hopefully will encourage a further increase on AIM this Thursday.Fingers crossed.

Edit: I agree with freemoney1

[freemoney1] 01/3/2017 17:59

More Sarepta investors realising where the real DMD potential is maybe ?
Good volume behind the US rise too.

[euroto] 01/3/2017 17:10

Indeed :-)

[euroto] 01/3/2017 16:17

You need to recognise the BBS agendas Luminoso, you don't have to agree or disagree with them just like the press.

[luminoso] 01/3/2017 15:51

"BBC - low standards in the journalism dept" eh ?
What, lower even than the Daily Mail and almost all the rest of Fleet St and TV ?
Utter tosh and politically motivated comment. They all underperform most of the time and get it right just a bit of the time.

[chrisatrdg] 01/3/2017 13:46

Summit pre market on NASDAQ but on only 50 Vol is at $13 (up 6.47%) & Serepta is down by 4.4% (amended) on higher activity.Fingers crossed.

[euroto] 01/3/2017 12:33

I would not take too much notice of what is on the BBC - low standards in the journalism department often lead to them just re-working old news about antibiotics not being effective. Follows a pattern with them these days of lack of research . Spend too much time pumping equality and anti Trump.

[football] 01/3/2017 11:09

There was a article in and I'm not sure if it was the BBC/Evening Standard website about a week ago about antibiotics not working anymore within 10 years and having to find new antibiotics or ways of making the ones we have work better a week or so ago so maybe this is where C. diff will come in and stop the re-infection

[freemoney1] 01/3/2017 11:01

I think they are focussed on the resistant bacteria.
They have antibiotics to beat C.Diff but the problem is those antibiotics kill the other good stuff too.
So Ridinilazole solves a slightly different by still high unmet need problem.

[hugus maximus] 01/3/2017 10:16

Hi Waterloo & Football:

Edit.

Apologies ... I stand down .... C Diff is wrongly quoted by that ABC News Network Report in an all encompassing comment including C Diff with MRSRA ... this is the actual WHO press release:

hxxp://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/

Indeed why isn't C Diff included here?

[football] 01/3/2017 09:49

Nor could I was hoping that someone would see it in one of the critical, high or medium or may be attributed to one of the categories

[waterloo01] 01/3/2017 09:28

Sorry just can't see any mention of C.diff

[football] 01/3/2017 09:01

WHO publishes list of bacteria for which new antibiotics are urgently needed

News release

27 FEBRUARY 2017 | GENEVA - WHO today published its first ever list of antibiotic-resistant "priority pathogens" – a catalogue of 12 families of bacteria that pose the greatest threat to human health.

[hugus maximus] 01/3/2017 08:57

LSE BB ... should I have said the "other side"?

[hugus maximus] 01/3/2017 08:24

Interesting post from 'whitespirit' on the other channel.

WHO list C Diff as one of its top 12 priorities in need of antibiotic fix:

[abergele] 28/2/2017 22:19

We're just waiting for those precious words.."success"..and this will rocket.
and I am staying aboard very confident

[chrisatrdg] 28/2/2017 12:17

RNS Today

It seems to me Summit are showing a positive spin on developments with DMD (SP Increases).

SUMMIT THERAPEUTICS RECOGNISES TENTH ANNUAL RARE DISEASE DAY

Summit Therapeutics plc

('Summit' or 'the Company')

SUMMIT THERAPEUTICS RECOGNISES 10TH ANNUAL RARE DISEASE DAY

Oxford, UK, 28 February 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and Clostridium difficile infection, recognises the tenth annual Rare Disease Day taking place today, 28 February 2017. The Rare Disease Day 2017 theme, 'with research, possibilities are limitless,' emphasises the importance of scientific research in helping to understand, diagnose and treat rare diseases that affect millions of people and their families worldwide.

Summit seeks to remain at the forefront of utrophin modulation research through its strategic alliance with the University of Oxford, under the guidance of Professor Kay Davies. The collaboration is focussed on developing future-generation utrophin modulators for the potential treatment of all patients with the progressive muscle wasting disorder, DMD. To date, the research team has identified two series of novel utrophin modulators, one of which has a mechanism of action potentially distinct from ezutromid, the Company's lead utrophin modulator that is in a Phase 2 clinical trial in DMD patients.

"In our quest to bring a potentially disease-modifying treatment to all patients with DMD, we have collaborated with the preeminent expert in utrophin modulation biology, Professor Kay Davies, and her research team at the University of Oxford," said Glyn Edwards, Chief Executive Officer of Summit. "We applaud EURORDIS, the organisation representing rare disease patients in Europe, for bringing an annual spotlight to the plight of millions of people affected by rare diseases and in this year, recognising the immense impact that research is having and will continue to have for those living with rare diseases."

In the European Union a rare disease is defined as one that affects fewer than 5 in 10,000 of the general population, while in the United States, it is defined as a disease that affects fewer than 200,000 people. There are between 6,000 and 8,000 known rare diseases with around five new rare diseases described in the literature each week. Rare diseases are often chronic and life threatening and include rare conditions, such as childhood cancers, and some other well-known conditions including cystic fibrosis and DMD.

Rare Disease Day takes place on the last day of February each year, and its objective is to raise awareness among the general public and decision-makers about rare diseases and their impact on patients' lives. Rare Disease Day was launched in Europe in 2008 by EURORDIS. It is now observed in more than 80 nations, and is sponsored in the US by the National Organization for Rare Disorders (NORD). For more information, please visit www.rarediseaseday.org.

[abergele] 27/2/2017 20:07

Thanks Luminoso,keeping us up to speed,all moving well over the pond so far today/night,a day to look forwards too,,we may have to take some more before they get too expensive a commodity to buy,,says he joyfully....gla lth's

[luminoso] 27/2/2017 17:11

We are bound to lag behind by a day. Because the Nasdaq is so volatile, the mm's are not going to mark it up at end of day based on early action on Nasdaq. The dollar is at 1.247 to the pound. Current smmt price is pretty much £2, so we are not far behind really.
Edit....and rising. :-)

[football] 27/2/2017 15:45

But you wouldn't think it on this side of the pond

[waterloo01] 27/2/2017 15:41

Back to $12.50.